v3.26.1
SEGMENT INFORMATION
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
We are organized into three reporting segments. Operations that sell proprietary dispensing systems, drug delivery systems, sealing solutions and services to the prescription drug, consumer healthcare, injectables, active material science solutions and digital health markets form our Pharma segment. Operations that sell dispensing systems and sealing solutions to the fragrance, facial skincare, color cosmetics, personal care and home care markets form our Beauty segment. Operations that sell dispensing closures, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and other markets form our Closures segment. The Pharma and Beauty segments are named for the markets they serve with multiple product platforms, while the Closures segment is named primarily for a single product platform that serves all available markets.
The accounting policies of the segments are the same as those described in Part II, Item 8, Note 1 - Summary of Significant Accounting Policies in our Annual Report on Form 10-K for the year ended December 31, 2025. Our chief operating decision maker ("CODM") is our President and Chief Executive Officer, Stephan Tanda. Our CODM is provided operating reports from each of our reportable segments which include or can be used to easily derive significant segment expenses identified as selling, research & development and administrative expenses and cost of sales by segment. Additionally, the other segment items primarily consist of foreign currency gains or losses from operations and other non-operating activity. Our CODM evaluates performance of our reporting segments and allocates resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, gain on remeasurement of equity method investment, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items if any. Adjusted EBITDA provides useful information regarding the performance of each segment as it reflects the profitability and performance of each segment on a consistent and comparable basis, and our CODM considers budget-to-actual variances on a monthly basis when making decisions supporting capital resource allocation, including in connection with development, acquisition and disposition activities in each segment.
Financial information regarding our reporting segments is shown below:
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Total Sales:
Pharma$458,321 $442,817 $897,229 $852,514 
Beauty377,426 342,251 749,584 654,552 
Closures202,560 190,278 384,752 364,199 
Total Sales$1,038,307 $975,346 $2,031,565 $1,871,265 
Less: Intersegment Sales:
Pharma$154 $228 $502 $458 
Beauty9,972 7,402 18,495 13,996 
Closures1,673 1,707 3,192 3,497 
Total Intersegment Sales$11,799 $9,337 $22,189 $17,951 
Net Sales:
Pharma$458,167 $442,589 $896,727 $852,056 
Beauty367,454 334,849 731,089 640,556 
Closures200,887 188,571 381,560 360,702 
Net Sales$1,026,508 $966,009 $2,009,376 $1,853,314 
Less:
Cost of Sales (exclusive of depreciation and amortization):
Pharma243,537 224,879 472,073 430,016 
Beauty270,862 241,378 542,350 465,426 
Closures146,864 133,362 278,747 255,753 
Selling, Research & Development and Administrative:
Pharma65,145 60,703 133,261 123,186 
Beauty52,846 48,738 105,476 95,150 
Closures24,707 23,858 49,652 46,870 
Other Segment Items:
Pharma(4,420)176 (8,735)(427)
Beauty(996)(2,340)(1,961)(4,231)
Closures(533)(532)(345)(1,064)
Adjusted EBITDA (1):
Pharma$153,905 $156,831 $300,128 $299,281 
Beauty44,742 47,073 85,224 84,211 
Closures29,849 31,883 53,506 59,143 
Adjusted EBITDA for Reportable Segments$228,496 $235,787 $438,858 $442,635 
Corporate & Other, unallocated(15,909)(17,378)(37,386)(40,889)
Acquisition-related costs (2)(38)(344)(228)(344)
Restructuring Initiatives (3)(1,419)(1,579)(2,505)(3,621)
Net unrealized investment gain (loss) (4)849 2,102 (237)1,006 
Other special items (5)(4,077)— (7,804)— 
Depreciation and amortization(79,641)(69,904)(155,366)(135,551)
Interest Expense(16,001)(10,850)(32,943)(22,201)
Interest Income2,787 1,880 6,429 4,694 
Income before Income Taxes$115,047 $139,714 $208,818 $245,729 
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Depreciation and Amortization:
Pharma$39,260 $34,169 $74,903 $65,317 
Beauty24,750 21,475 49,473 41,537 
Closures14,527 13,447 28,751 27,022 
Depreciation and Amortization for Reportable Segments78,537 69,091 153,127 133,876 
Corporate & Other1,104 813 2,239 1,675 
Depreciation and Amortization$79,641 $69,904 $155,366 $135,551 
Capital Expenditures:
Pharma
$27,694 $30,124 $56,585 $59,575 
Beauty
18,774 15,448 38,973 31,590 
Closures
8,150 15,613 21,894 26,085 
Capital Expenditures for Reportable Segments54,618 61,185 117,452 117,250 
Corporate & Other3,427 3,135 6,132 6,068 
Transfer of Corporate Expenditures (6)(482)(895)(625)(3,031)
Capital Expenditures$57,563 $63,425 $122,959 $120,287 
________________________________________________
(1)We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, gain on remeasurement of equity method investment, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items.
(2)Acquisition-related costs include transaction costs (and purchase accounting adjustments related to acquisitions and investments).
(3)Restructuring Initiatives includes expense items for the three and six months ended June 30, 2026 and 2025 as follows (see Note 18 – Restructuring Initiatives for further details):
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Restructuring Initiatives by Segment:
Pharma$(66)$68 $(61)$258 
Beauty1,417 626 2,718 1,021 
Closures87 890 336 2,242 
Corporate & Other(19)(5)(488)100 
Total Restructuring Initiatives$1,419 $1,579 $2,505 $3,621 
(4)Net unrealized investment gain (loss) represents the change in fair value of our investment in PCT (see Note 17 – Investment in Equity Securities for further details).
(5)Other special items includes costs related to non-ordinary-course litigation regarding the matters disclosed under "Legal Proceedings" within Note 12 - Commitments and Contingencies, as these costs do not reflect our core operating performance.
(6)The transfer of corporate expenditures represents amounts of projects managed by corporate for the benefit of specific entities within each segment. Once the projects are complete, all related costs are allocated from corporate to, and paid by, the appropriate entity and the associated assets are then depreciated at the entity level.